A 0001

Drug Profile

A 0001

Alternative Names: A-0001; alpha-tocopherol quinone; EPIA-0001

Latest Information Update: 26 Mar 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Edison Pharmaceuticals
  • Developer Endo Pharmaceuticals
  • Class Coenzymes; Eye disorder therapies; Neuropsychotherapeutics
  • Mechanism of Action Mitochondrial membrane transport protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia

Highest Development Phases

  • Discontinued Friedreich's ataxia; MELAS syndrome

Most Recent Events

  • 29 Feb 2012 Discontinued - Phase-II for Friedreich's ataxia in USA (PO)
  • 29 Feb 2012 Discontinued - Phase-II for MELAS syndrome in England (PO)
  • 11 Jun 2011 Pharmacodynamics, adverse event and preliminary efficacy data from a phase IIa trial in Friedreich's ataxia released by Edison Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top